Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome and is associated with reduced GPX4 promoter hypermethylation - PubMed
14 hours ago
- #PCOS
- #Semaglutide
- #Ferroptosis
- Semaglutide alleviates ovarian ferroptosis in polycystic ovary syndrome (PCOS).
- The study links semaglutide's effects to reduced GPX4 promoter hypermethylation.
- PCOS is associated with ovarian granulosa cell dysfunction and ferroptosis, a regulated cell death driven by lipid peroxidation.
- GLP-1 receptor agonists (GLP-1 RAs) like semaglutide improve metabolic features of PCOS and show direct effects on ovarian ferroptosis.
- Animal models (rats and mice) treated with exenatide or semaglutide showed alleviation of PCOS phenotypes and reversal of ferroptosis markers.
- Semaglutide restored GPX4 expression and reduced GPX4 promoter hypermethylation, with efficacy comparable to 5-azacytidine.
- In vitro studies confirmed semaglutide's ability to correct DHT-induced GPX4 hypermethylation and ferroptosis in granulosa cells.
- The findings suggest semaglutide offers direct ovarian protection via epigenetic modulation beyond metabolic benefits.